DRREDDY.NSE

Dr. Reddy`s Laboratories Ltd.

Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is manufactured by Dr. Reddy's Laboratories in India and is approved for the once-weekly treatment of Type 2 diab...

Hyderabad: Dr Reddy's Labs said Wednesday that Health Canada has approved its generic semaglutide injection, making it the first company to secure mar.

Hyderabad: Dr Reddy's Labs said Wednesday that Health Canada has approved its generic semaglutide injection, making it the first company to secure mar.

Indian equity markets opened weak on Friday amid persistent geopolitical tensions and the ongoing Q4 earnings season. Sensex fell 400 points to 77,263, while Nifty declined 100 points in early trade. IT, financial, and pharma stocks faced heavy selling pressure, with Cipla, Infosys, Dr Reddy’s, Sun Pharma, TCS, and ICICI Bank as top laggards. FMCG and chemical stocks provided some support.

Indian equity markets opened weak on Friday amid persistent geopolitical tensions and the ongoing Q4 earnings season. Sensex fell 400 points to 77,263, while Nifty declined 100 points in early trade. IT, financial, and pharma stocks faced heavy selling pressure, with Cipla, Infosys, Dr Reddy’s, Sun Pharma, TCS, and ICICI Bank as top laggards. FMCG and chemical stocks provided some support.

In this briefing: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Sharda Cropchem is an asset-light agrochemical supplier that sources products mainly from China and India, sells globally, and builds competitive advantage through extensive regulatory product registrations instead of manufacturing capabilities. They invest heavily in product registrations, creating large pipeline that converts into revenue over time, driving strong cash flows funding growth internally, and supporting dividends despite high accounting amortization charges. Sharda’s massive registration pipeline and presence in regulated markets drive growth despite sourcing and forex risks.

In this briefing: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Sharda Cropchem is an asset-light agrochemical supplier that sources products mainly from China and India, sells globally, and builds competitive advantage through extensive regulatory product registrations instead of manufacturing capabilities. They invest heavily in product registrations, creating large pipeline that converts into revenue over time, driving strong cash flows funding growth internally, and supporting dividends despite high accounting amortization charges. Sharda’s massive registration pipeline and presence in regulated markets drive growth despite sourcing and forex risks.

In this briefing: Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan 1. Primer: Anthem Biosciences (1234D IN) - Apr 2026 Anthem Biosciences is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end services for small and large molecules to the global pharmaceutical and biotechnology sectors. The company has demonstrated a strong financial track record, with a 32% CAGR in operating revenue between FY23 and FY25, and boasts industry-leading EBITDA margins. Key growth drivers include its leadership in fermentation capacity in India, expertise in advanced therapeutic modalities like ADCs and RNAi, and a strategic focus on backward integration to reduce reliance on external suppliers.

In this briefing: Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan 1. Primer: Anthem Biosciences (1234D IN) - Apr 2026 Anthem Biosciences is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end services for small and large molecules to the global pharmaceutical and biotechnology sectors. The company has demonstrated a strong financial track record, with a 32% CAGR in operating revenue between FY23 and FY25, and boasts industry-leading EBITDA margins. Key growth drivers include its leadership in fermentation capacity in India, expertise in advanced therapeutic modalities like ADCs and RNAi, and a strategic focus on backward integration to reduce reliance on external suppliers.